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INTRODUCTION
Very little progress has been made in the treatment of pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer-related deaths in the U.S. (1) .
Since pancreatic cancer causes minimal early signs or symptoms, most patients present with locally advanced or metastatic disease at the time of diagnosis (2) . The primary treatment option for patients with advanced disease includes chemotherapy, with gemcitabine as the preferred therapy. Despite being the first line treatment for patients with PDAC, majority of the patients do not benefit from gemcitabine (3) . Molecular targeted therapies have failed to show a clinically significant improvement over gemcitabine alone (4) , raising an urgent need to understand the reasons for the poor response of PDAC tumors to current therapeutic agents.
Gemcitabine, a nucleoside analog that competes with cytidine during DNA replication, has been shown to activate cell cycle checkpoints that allow cells time for repair and determine whether to progress through the cell cycle or to undergo apoptosis. Gemcitabine activates Chk1 and Chk2 kinases, key effectors of the checkpoint response (5) . Activation of Chk1 during DNA replication stalls cell cycle progression, prevents premature mitotic entry and allows time to repair the damaged DNA. Cells resistant to arrest continue replicating despite the accumulated double-strand breaks, resulting in cells with mutations progressing through the cell cycle, causing genomic instability. Although Chk1 and Chk2 were initially thought to have specific roles, Chk2 may be redundant in checkpoint activation and may primarily modulate Chk1 responses (6).
Human pancreatic cancers are associated with an intense fibrotic reaction, the encasing tissue composed of interstitial extracellular matrix (ECM) and proliferating stromal cells. The fibrotic reaction was recently shown to limit the delivery and efficacy of gemcitabine in a mouse model of pancreatic cancer (7, 8) . It also contributes to the malignant phenotype of PDAC (9) part by increasing expression of the proteinase membrane type-1 matrix metalloproteinase (MT1-MMP) (10) . PDAC is also associated with increased expression of high mobility group A2 (HMGA2), a non-histone DNA-binding protein involved in chromatin remodeling and gene transcription (11) . HMGA2 is increased in high-grade pancreatic tumors with lymph node metastases (12) , and consistent with it's role in pancreatic cancer invasion, HMGA2 is involved in maintaining Ras-induced epithelial-mesenchymal transition (13) . HMGA2 also modulates expression of genes that are important for cell proliferation, DNA repair and apoptosis (14, 15) .
In this report we examine the mechanism by which collagen promotes gemcitabine resistance. We show that the 3D collagen microenvironment protects PDAC cells from gemcitabine-induced proliferation-and cell cycle-arrest. The effect of collagen is mediated through increased MT1-MMP-dependent ERK1/2 phosphorylation and HMGA2 expression. Panc1 and CD18 cells inducibly expressing MT1-MMP were generated as previously described (17) .
Transfection -Cells were transfected with siRNA against MT1-MMP, HMGA2 or control siRNA (50 nmoles) or the pre-miR to let-7 or pre-miR negative control (at 50 nmoles) using Nucleofector Kit R (Lonza), allowed to recover overnight and then plated either on plastic or in 3D collagen gels (2 mg/ml). Alternatively, cells were transfected using RNAimax (Invitrogen) according to manufacturer's instructions before plating into collagen.
Proliferation assay -Proliferation by
3 H-thymidine incorporation was measured as previously described (18) . (17) . Similarly, expression of let-7a/d/g and RNU48 was analyzed as previously published (19) .
Immunoblotting -Immunoblotting was done as previously described (10) . For cells grown in collagen, the matrix was first dissolved in collagenase (Worthington Biologicals, Lakewood, NJ) and then lysed as previously described (10) .
Zymography -MT1-MMP activity analysis was done by SDS-PAGE gelatin zymography as described previously (17) . Human pancreatic tumor samples -Pancreatic tissue was obtained from patients with PDAC on an IRB-approved protocol. Cancerous and adjacent normal tissue samples were dissected and processed for RNA extraction using Trizol. RNA quality was checked using Bioanalyzer-309 and samples with RNA Integrity Number (RIN) greater than 6 were used for gene expression studies.
Subcutaneous tumor studies -
Statistical analysis -All statistical analyses were done using GraphPad Instat 3 (San Diego, CA) and Microsoft Excel (student's t-test).
RESULTS

3D type I collagen protects PDAC cells from gemcitabine-induced cell cycle arrest.
Recently it was demonstrated that the effect of gemcitabine was reduced by the fibrotic reaction in a mouse model of pancreatic cancer (7). To identify whether type I collagen, the most common ECM present in the fibrotic reaction, contributes to chemoresistance, we treated PDAC cells (Panc1, CD18 and AsPC1) grown on plastic or in 3D collagen with low levels of gemcitabine (100 μM) for 24 hours and assessed proliferation by 3 H-thymidine incorporation.
As seen in Fig. 1A , while only a minority of cells on plastic proliferate following gemcitabine treatment, most cells in 3D collagen continue to proliferate in the presence of gemcitabine. In the absence of gemcitabine, 3D collagen had no effect on proliferation (Fig. 1B) . We also examined the effect of gemcitabine on checkpoint activation by immunoblotting for Chk1 phosphorylation on Ser345. Cells growing in collagen displayed minimal activation of Chk1 compared to the robust Chk1 activation in cells grown on plastic ( collagen gels and then treated with gemcitabine. Chk1 phosphorylation was similar between cells grown on plastic and on 3D collagen (Fig. 1D) . However, compared to cells grown on 3D collagen, there was a significant reduction in Chk1 phosphorylation in cells grown in 3D (Fig.   1E ). To determine whether the effect of the 3D microenvironment on checkpoint activation was unique to collagen or applicable to other matrices, we also examined the effect of 3D matrigel on checkpoint activation. As shown in Supplemental Fig. S2 , cells grown in 3D matrigel showed similar response as in 3D collagen, indicating that the effect is mediated by the 3D microenvironment. Since collagen is the predominant ECM in human PDAC tumors, we conducted subsequent experiments in 3D collagen gels. of collagen on gemcitabine-induced Chk1 phosphorylation (Supplemental Fig. S3D ), indicating that let-7 and HMGA2 differentially affect Chk1 phosphorylation in collagen.
The interplay between ERK1/2 and HMGA2 contributes to gemcitabine resistance of PDAC cells in collagen. The MEK/ERK1/2 signaling pathway is known to be responsible for promoting survival signals, and blocking ERK1/2 phosphorylation with U0126 increases gemcitabine sensitivity (23, 24) . Since Panc1 cells grown in collagen showed increased ERK1/2 phosphorylation compared to cells grown on plastic (Fig. 3A) , we examined the effect of U0126 on collagen regulation of Chk1 phosphorylation. Treatment with U0126 inhibited collagen-induced ERK1/2 activation and HMGA2 expression (Fig. 3B) , enhanced gemcitabineinduced Chk1 phosphorylation in Panc1 cells (Fig. 3C , top) and reduced proliferation (Fig. 3C,   bottom) . Interestingly, knocking down HMGA2 in Panc1 cells grown in collagen also decreased ERK1/2 phosphorylation (Fig. 3D) , suggesting that a feed-back loop exists between HMGA2 and ERK1/2 to help sustain ERK1/2 phosphorylation in the collagen microenvironment. 
MT1-MMP. Knocking-down MT1-MMP also decreased collagen-induced ERK1/2 phosphorylation (Fig. 4C ) and HMGA2 expression (Fig. 4D) . stained with H&E, with trichrome to assess fibrosis, and for PCNA to examine proliferation.
MT1-MMP
There was robust MT1-MMP expression in CD18-MT1-MMP and Panc1-MT1-MMP tumors relative to the corresponding control tumors (data not shown). Consistent with previous reports that MT1-MMP-expressing tumors demonstrate increased stromal reaction (17, 25) , there was also increased stromal reaction in the MT1-MMP-expressing PDAC tumors (Fig. 6A) .
Additionally, there was suggestion of increased collagen in the MT1-MMP-expressing tumors as indicated by the increased blue staining in the trichrome images (Fig. 6B) . Although there was no difference in the size of these tumors or their proliferation in the absence of gemcitabine treatment, MT1-MMP-overexpressing PDAC tumors displayed greater proliferation relative to control PDAC tumors following gemcitabine treatment (Figs. 6C and 6D ). The gemcitabine treatment regimen used for these animal studies did not induce apoptosis, and given the short duration of these animal studies no difference in tumor size was detected (data not shown).
We next examined whether switching off MT1-MMP in established tumors increases the sensitivity of PDAC cells to gemcitabine. CD18 cells expressing vector or ΔC were injected into nude mice and the mice were maintained on doxycycline for 2 weeks to induce MT1-MMP. (26) . In our study we delineate the mechanism by which collagen reduces the effectiveness of gemcitabine in pancreatic cancer. The effect of collagen on checkpoint arrest was seen primarily in the 3D collagen microenvironment and was not detected atop 3D gels, suggesting the importance of 3D tumor microenvironment in regulating cellular response. Cells in 3D matrigel also showed attenuation of gemcitabine response, further demonstrating the importance of 3D microenvironment. The differential effect of on collagen versus in collagen could be because of decreased penetration of gemcitabine into 3D collagen gels; however, it is now well established that cells respond differently to 2D surfaces versus 3D environments, and activate distinct pathways on 2D tissue culture plastic versus in 3D gels (27, 28) .
We show that 3D collagen increases HMGA2 and thereby attenuates the effect of gemcitabine. Expression of HMGA1 has been shown to be a determinant of chemoresistance in pancreatic adenocarcinoma (29, 30) , but a role for HMGA2 is yet to be established. Although HMGA2 can sensitize breast cancer and salivary epithelial cells to doxorubicin (31) , it can also protect cancer cells against DNA damage induced cytotoxicity. HMGA2 is part of the base endjoin repair machinery that removes small damaged bases from the DNA, and has an apurinic/apyrimidinic lyase activity to protect against the effects of chemotherapy (21) . HMGA2 contributes to genomic instability and tumor progression by inhibiting the DNA repair enzyme DNA-dependent protein kinase during the non-homologous DNA end joining repair process (32) . HMGA2 has been shown to maintain cancer stem cells in their undifferentiated state (33) We have found that collagen-induced HMGA2 induction involves ERK1/2 signaling, which agrees with a previous report showing that Raf-1-and PMA-induced HMGA2 expression was blocked by the MEK1/2 inhibitor PD98059 (34). ERK1/2 was also shown to upregulate HMGA2 in metastatic breast cancer cells (19) , while inhibition of ERK1/2 decreased HMGA2 levels in PDAC cells (13) . The MEK/ERK signaling pathway promotes chemotherapy resistance in a number of different cancers including multiple myeloma (35) , hepatocellular carcinoma (23) and pancreatic cancer (24) . Inhibition of ERK1/2 signaling can also sensitize cancer cells to chemotherapy (36) . Here we show that inhibiting ERK1/2 decreased collagen-induced HMGA2 induction and sensitized cells to gemcitabine-induced checkpoint and proliferation arrest.
Interestingly, we found that HMGA2 may function to sustain ERK1/2 phosphorylation, as downregulation of HMGA2 decreased ERK1/2 activation by collagen. These findings demonstrate that the interplay between HMGA2 and ERK1/2 contributes to attenuating the effect of gemcitabine in the collagen microenvironment.
HMGA2 is also regulated by the let-7 family of microRNAs which can bind to the 3'UTR of HMGA2 and cause degradation of HMGA2 mRNA (22, 37) . Although let-7 is a negative regulator of HMGA2 in PDAC cells, and we recently showed that MT1-MMP in turn inhibits let-7 in collagen (38) , expression of pre-miR let-7 did not abrogate the effect of gemcitabine in the collagen microenvironment. Interestingly, a recent report showed that there was differential regulation of epithelial-mesenchymal transition and proliferation by HMGA2 and let-7 in pancreatic cancer cells (13) . Knocking down HMGA2 with siRNA reversed the mesenchymal phenotype of pancreatic cancer cells and decreased proliferation; however, expression of let-7 did not affect EMT or proliferation even though HMGA2 levels were decreased (13). Overall, we demonstrate that the collagen-rich tumor microenvironment limits the effectiveness of gemcitabine through MT1-MMP-mediated HMGA2 expression as depicted by our model (Fig. 7) . MT1-MMP is overexpressed in human PDAC tumors, particularly in areas of fibrosis. We now show that MT1-MMP expression is associated with increased HMGA2 expression in human PDAC tumors, suggesting that the pronounced fibrotic reaction may contribute to gemcitabine resistance through increased MT1-MMP-HMGA2 signaling. Given that very little progress has been made in the treatment of pancreatic cancer, targeting MT1-MMP could be a novel approach to sensitize pancreatic tumors to gemcitabine. 
